A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of …
J Overgaard, HS Hansen, M Overgaard… - Radiotherapy and …, 1998 - Elsevier
Purpose: A multicenter randomized and balanced double-blind trial with the objective of
assessing the efficacy and tolerance of nimorazole given as a hypoxic radiosensitizer in
conjunction with primary radiotherapy of invasive carcinoma of the supraglottic larynx and
pharynx. Patients and treatment: Between January 1986 and September 1990, 422 patients
(414 eligible) with pharynx and supraglottic larynx carcinoma were double-blind randomized
to receive the hypoxic cell radiosensitizer nimorazole, or placebo, in association with …
assessing the efficacy and tolerance of nimorazole given as a hypoxic radiosensitizer in
conjunction with primary radiotherapy of invasive carcinoma of the supraglottic larynx and
pharynx. Patients and treatment: Between January 1986 and September 1990, 422 patients
(414 eligible) with pharynx and supraglottic larynx carcinoma were double-blind randomized
to receive the hypoxic cell radiosensitizer nimorazole, or placebo, in association with …